Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.33 |
| ▸ | CNR2 | P34972 | 7/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CKS1B | P61024 | 1/20 | 0.30 |
| ▸ | SKP1 | P63208 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18544643 | 0.87 | AKT1 (0.31) | — | |
| SCHEMBL24340762 | 0.81 | MGLL (0.32) | — | |
| SCHEMBL18544644 | 0.80 | USP2 (0.35) | — | |
| SCHEMBL22135513 | 0.80 | MGLL (0.33) | ALDH1A1 | |
| SCHEMBL23207887 | 0.80 | — | — | |
| SCHEMBL24340893 | 0.79 | MGLL (0.32) | — | |
| SCHEMBL24340793 | 0.79 | SMN1; SMN2 (0.41) | CNR1 | |
| SCHEMBL24183327 | 0.79 | — | — | |
| SCHEMBL25839706 | 0.79 | AKT1 (0.33) | — | |
| SCHEMBL26017312 | 0.78 | TNKS (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049908-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE LLC (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049908-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | ENTPD1, ENTPD2, ENTPD3 | CNR1 633/4885CNR2 512/4885ALDH1A1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.